CXCR1 and neoplasm: Thus, combination therapy, such as radiotherapy plus SX-682 (CXCR1/2 inhibitor) (84), could abrogate the recruitment of tumor MDSCs and enhance the tumor infiltration and therapeutic efficacy of NK cells.